Remdesivir and tixagevimab plus cilgavimab for treating COVID-19

Final draft guidance: TA971

Final draft guidance (PDF 522 KB)

Committee papers (PDF 2.47 MB)

Public committee slides (PDF 520 KB)

Draft guidance: TA971

Appraisal consultation document (PDF version) (PDF 495 KB)

Appraisal consultation document (online commenting)

Committee papers (PDF 4.37 MB)

Public committee slides (PDF 1.97 MB)

Consultation documents published: Consultation on the in vitro data on neutralising monoclonal antibodies for COVID-19: methods framework

Consultation document - In vitro methods framework October 2023 (PDF 749 KB)

Appeal

AstraZeneca : Appeal letter (MSWord 43 KB)

Gilead : Appeal letter (MSWord 188 KB)

Merck Sharp & Dohme : Appeal letter (PDF 2.01 MB)

Gilead : Scrutiny letter (MSWord 93 KB)

Merck Sharp & Dohme : Scrutiny letter (MSWord 87 KB)

Gilead : Response to scrutiny letter (MSWord 147 KB)

Merck Sharp & Dohme : Response to scrutiny letter (PDF 293 KB)

Gilead : Final scrutiny letter (MSWord 64 KB)

Merck Sharp & Dohme : Final scrutiny letter (MSWord 70 KB)

Final draft guidance: TA878

Final appraisal document (PDF 518 KB)

Committee papers (PDF 10.21 MB)

Public committee slides (PDF 1.95 MB)

Draft guidance: TA878

Appraisal consultation document (PDF version) (PDF 391 KB)

Appraisal consultation document (online commenting)

Committee papers (PDF 15.32 MB)

Committee meeting: 4 - TA971

Final scope (PDF 249 KB)

Final stakeholder list (PDF 174 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 1.35 MB)

Equality impact assessment (Scoping) (PDF 137 KB)

Final scope (PDF 246 KB)

Provisional Stakeholder List (post-referral) (PDF 172 KB)

Final protocol (PDF 384 KB)

Supporting documentation - Stakeholder Information Meeting slides (PDF 212 KB)

Draft scope pre referral (PDF 251 KB)